The majority, over 90% of the wild-type KMT2A ALL cases, occur as CD10-positive B-lymphoblastic leukemia [21] and 4–10% as T-lymphoblastic leukemia [22]. This evidence concerns the gene MME and acute lymphoblastic leukemia.